Availability of Cost Effectiveness Information on the Highest-Cost Drugs and Procedures in the United States

Abstract

Objectives: The SF6D is a preference-based measure designed to calculate QALY. Preference-based measures are standardized multidimensional health state classifications with preference or utility weights elicited from a sample of the population. There is actually a concern that valuations may differ between countries because of differences in culture, thus invalidating the use of values obtained from one country in another. The aim of this article is to assess whether these valuations differ from one country to another for the SF6D. MethOds: We performed a systematic review of articles that developed value sets for the SF6D. The data search was conducted in PubMed, ScienceDirect and Scopus. This search was completed by a scanning of the researchgate page of John Brazier, inventor of the SF6D, and of the SF6D webpage hosted by the University of Sheffield. The search was performed up to November 2014 and all languages were considered. The quality of the articles was assessed with the CREATE checklist developed by Xie et al. (2014). Methodological differences were assessed. Results: From a total of 466 articles, 21 were selected. This corresponded to 8 different countries (UK,

Concerns Around Budget Impact Thresholds: Not All Drugs Are the Same

“…First, efficient reallocation of resources requires that cost-effectiveness be known for both the therapy with spending over the cap and the service/therapy to which spending will be reallocated. A review of US-specific cost-effectiveness analysis in Tuft's Medical Center Cost Effectiveness Analysis Registry, however, found that this information is often missing for both the top procedures and drugs [9], which makes efficient reallocation of resources difficult. For example, cost-effectiveness data for serotoninnorepinephrine reuptake inhibitors, which were present in the list of drugs that exceeded the $904 million spending cap, were either not available or not available in a timely manner (relative to launch).…”